COVID-PACT is a multicenter, randomized, open-label, 2 x 2 factorial design trial of full-dose anticoagulation vs. standard-dose prophylactic anticoagulation and antiplatelet therapy vs. no antiplatelet therapy on the risk of venous or arterial thrombotic events in ICU patients with COVID-19. Study patients will be followed until their 28th day or hospital discharge, whichever comes first.
MAIN RESULTS:
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients with COVID-19: COVID-PACT
MAIN RESULTS PRESENTATIONS
COVID-PACT Primary Results (Berg, ESC 2022)
COVID-PACT on ClinicalTrials.gov
CONTACT US about COVID-PACT
TIMI STUDY GROUP 